Caleb DesRosiers, JD, MPA Appointed to Daxor Corporation Board of Directors
21 janv. 2022 08h00 HE
|
Daxor Corporation
Oak Ridge, TN, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announced today that it has appointed Caleb DesRosiers, JD,...
Daxor Corporation to Commence Trading on The Nasdaq Capital Market On February 2, 2022
20 janv. 2022 16h05 HE
|
Daxor Corporation
Oak Ridge, TN, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that it will commence trading on The Nasdaq...
Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
06 janv. 2022 08h00 HE
|
Daxor Corporation
Oak Ridge, TN, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that CEO and President Michael Feldschuh...
DAXOR ANNOUNCES KEY MILESTONES ACHIEVED FOR MULTICENTER BVA-100® STUDY IN HOSPITALIZED PATIENTS WITH COVID-19
05 janv. 2022 08h00 HE
|
Daxor Corporation
Patient Enrollment Complete and Data Analysis Commences with Daxor’s Blood Volume Analysis Technology Oak Ridge, TN, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the...
DAXOR AWARDED NEW PATENT FOR BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES
04 janv. 2022 08h00 HE
|
Daxor Corporation
Method Patent Covers Blood Volume Analysis Technology to Evaluate and Guide Treatment Decisions in Multiple Medical Conditions Oak Ridge, TN, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation...
Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Optimal Heart Failure Management at Key Scientific Society Meeting
16 nov. 2021 08h00 HE
|
Daxor Corporation
Two New Studies Presented at the American Heart Association Scientific Sessions 2021, Adoption of Technology Reported as “Excellent” and “Valuable” by Lead Authors Oak Ridge, TN, Nov. 16, 2021 ...
New Research Demonstrates Clinical Utility of Daxor Corporation Blood Volume (BVA-100®) Diagnostic in Neurocritical Care
09 nov. 2021 08h00 HE
|
Daxor Corporation
Data Presented at the NeuroCritical Care Society 19th Annual Meeting 2021 Data Highlight Daxor’s Diagnostic Changes Care in 69% of Patients With Non-Traumatic Subarachnoid Hemorrhage (nSAH) NEW...
Daxor Corporation Receives $200K Matching Fund Award from Launch Tennessee
01 oct. 2021 08h30 HE
|
Daxor Corporation
The SBIR/STTR Matching Fund Grant Will Advance the Company’s Innovation and Commercialization Efforts, and Job Creation Oak Ridge, TN, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE:...
Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Heart Failure Patients at Key Scientific Society Meeting
14 sept. 2021 08h30 HE
|
Daxor Corporation
Data from Three New Studies and Two Ongoing Trials Presented at the Heart Failure Society of America Annual Scientific Meeting 2021 Data Highlight Importance of Blood Volume Analysis in Providing...
Daxor Corporation To Present Compelling New Data and Clinical Trials Utilizing the BVA-100® Blood Test at the Heart Failure Society of America Annual Scientific Meeting 2021
08 sept. 2021 08h30 HE
|
Daxor Corporation
Oak Ridge, TN, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, , today announced it will exhibit at the Heart Failure...